abstract
Future of Health Summit 2023

Will Digital Therapeutics Scale or Fail?

-

In 2021, digital therapeutics benefited from record-breaking investment, up 134 percent from the previous year and topping out at nearly $9 billion. In 2023, however, the poster child of digital therapeutics, with multiple FDA-approved products, filed for Chapter 11 bankruptcy protection, leaving investors wondering what the future holds. Is this a bellwether for future challenges facing the industry, or an opportunity to rethink how digital-native products can be distributed and reimbursed? Panelists will examine whether FDA approval should be encouraged for products in the digital space and if there are viable reimbursement models for these solutions. Finally, panelists will discuss the potential value of evidence-based digital health and the advantages digital-native products may have over their conventional counterparts.  

    Moderator

    Image

    Tina Reed

    Senior Health Care Reporter, Axios

    Speakers

    Image

    Robert DeLuca

    President, Orexo Pharmaceuticals
    Image

    Arun Gupta

    CEO, Big Health
    Image

    Julia Hu

    CEO and Co-Founder, Lark Health
    Image

    Matthew Stoudt

    CEO, AppliedVR, Inc.
    Image

    Troy Tazbaz

    Director, Digital Health Center of Excellence, US Food and Drug Administration